Novo Nordisk creates four senior vice presidents
pharmafile | February 1, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk
Novo Nordisk has promoted four corporate vice presidents within its ranks into senior vice presidents.
The following members of the US executive team will each assume the title within their respective areas: Andy Ajello (pictured), US National Diabetes Sales; Camille Lee, US Diabetes Marketing; Alan Moses, global chief medical officer; and Anne Phillips, US Clinical, Medical and Regulatory Affairs.
Jerzy Gruhn, president of Novo Nordisk said: “Our global leaders have recognised that certain positions within the US organisation now have such high impact on the company’s overall performance that they should be elevated to the senior vice president level.”
Ajello, Lee, Moses and Phillips will continue to serve on the US Executive Team, reporting to Gruhn. Moses will move to the company’s global headquarters in Denmark and report to Mads Krogsgaard Thomsen, executive vice president and chief science officer, later in 2013. All will become members of the firm’s senior management board.
Ajello has been in the pharma industry for nearly 20 years. He joined the team in March 2001 and currently leads the National Diabetes Sales strategy and the company’s 3,200 person (approx) field sales organisation.
Lee has more than 25 years of experience in the industry. She joined the company in 1985 as a sales representative in Southern California, and through her tenure with the company has held national and international positions of increasing authority in the areas of marketing, strategic launch planning, and sales management.
Moses joined Novo Nordisk in 2004 from Harvard Medical School and the Joslin Diabetes Center as associate vice president for clinical research and medical affairs – endocrinology, and in 2007 was named chief medical officer for North America.
Phillips brings more than 20 years of medical, research, and regulatory experience to her role. She currently leads an integrated drug development, medical, regulatory, and safety team of more than 550 people.
Related Content
CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …
Novo Nordisk shares positive results from COMBINE 3 phase 3a trial
Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …
